Novo Nordisk, the Danish pharmaceutical giant, is taking a new step to address affordability and adherence for patients using its popular weight-loss drugs, Wegovy, and Ozempic. On Tuesday, the company launched a multi-month subscription program designed to provide cash-paying customers with more predictable, and potentially lower, monthly costs. This move comes as demand for these GLP-1 receptor agonists continues to surge, and as Novo Nordisk prepares to face increased competition in the market for obesity and diabetes treatments.
The subscription model offers three-, six-, and 12-month plans for both the Wegovy injection and the two highest doses of the newly available Wegovy pill. According to Novo Nordisk, patients who opt for longer subscription terms can save up to $1,200 per year on the injection and $600 per year on the pill compared to purchasing each dose individually. A key benefit is price stability; subscribers will pay a flat monthly rate regardless of dosage adjustments during the subscription period.
The program is rolling out in partnership with several telehealth providers, including Ro, WeightWatchers, LifeMD, Sesame, and Hims & Hers, with plans to add more partners in the coming weeks. This collaboration aims to streamline access to Wegovy for patients who may not have a regular physician or who prefer the convenience of telehealth services. The launch of this subscription program for Wegovy reflects a broader industry trend toward innovative pricing models designed to improve patient access and affordability.
Addressing a Critical Challenge: Treatment Adherence
One of the significant hurdles in treating obesity with GLP-1 medications like Wegovy is maintaining long-term adherence. Research indicates that a substantial portion of patients discontinue treatment within the first year. A study published in JAMA Network Open estimated that around 65% of patients with obesity stop GLP-1 treatment within a year, as reported by CNBC. Factors contributing to this include the cost of the medication, difficulty accessing it, and the potential for gastrointestinal side effects.
“Inability to stay on GLP-1s is a longstanding issue,” explained Ed Cinca, Novo’s head of marketing and patient solutions. “This offering is an opportunity to help patients not only start but stay on therapy and help them manage the ups and downs of some of the pricing considerations.” By providing predictable costs and simplifying the refill process, Novo Nordisk hopes to improve patient retention and treatment outcomes.
Wegovy Pill Gains Traction, Competition Looms
Novo Nordisk launched the Wegovy pill in the U.S. In January, and it has quickly gained popularity. The pill format appeals to patients who prefer an oral medication over injections. However, the company is preparing for increased competition from Eli Lilly, which is expected to launch its own oral GLP-1 medication later this year. Currently, Eli Lilly holds an estimated 60% share of the branded GLP-1 market in the U.S., while Novo Nordisk has approximately 39%, according to Novo Nordisk.
The Wegovy pill has been particularly successful in attracting patients who were not previously using GLP-1 injections, making it crucial for Novo Nordisk to expand its patient base before Lilly’s competitor enters the market. The subscription program is a key component of this strategy, aiming to lock in patients and encourage long-term use.
Subscription Pricing Details
Here’s a breakdown of the Wegovy subscription pricing, as released by Novo Nordisk:
| Plan | Injection (Monthly Price) | Injection (Annual Savings) | Pill (Monthly Price) | Pill (Annual Savings) |
|---|---|---|---|---|
| 3-Month | $329 | $240 | $289 | $120 |
| 6-Month | $299 | $600 | $269 | $360 |
| 12-Month | $249 | $1,200 | $249 | $600 |
While the subscription program offers significant savings, cash-paying patients still have the option to purchase lower doses of the Wegovy pill (1.5mg and 4mg) for $149 per month. However, the price of the 4mg dose will increase to $199 per month starting in August. The recently approved 7.2mg dose of Wegovy will be added to the subscription program at a later date.
Novo Nordisk emphasizes that patients can cancel their subscriptions at any time without penalty. “We want to help patients identify a path that can help them feel comfortable about treating [obesity] in the long term,” Cinca added. The company is currently not offering the subscription program through its direct-to-consumer pharmacy, NovoCare, but is evaluating the possibility of expanding the program to that platform in the future.
Looking Ahead: Competition and Access
The launch of the Wegovy subscription program is a significant step toward improving affordability and access to these important medications. However, challenges remain. Supply chain issues have plagued the GLP-1 market, leading to shortages and limiting access for some patients. The upcoming competition from Eli Lilly will likely put further pressure on pricing and availability. The success of Novo Nordisk’s strategy will depend on its ability to navigate these challenges and continue to innovate in the rapidly evolving market for obesity and diabetes treatments.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The next key development to watch will be the launch of Eli Lilly’s oral GLP-1 medication later this year, which is expected to significantly reshape the competitive landscape. Readers are encouraged to share their thoughts and experiences with GLP-1 medications in the comments below.
